The U.S. Department of Justice may clamp down on life sciences companies that share board members with alleged competitors

The Biden administration is conducting investigations into potential antitrust violations to which the life sciences industry may be particularly vulnerable because having board members sit on more than one company is relatively common. Benjamin Nagin and Kristina Gliklad explain.

Biden Administration Moves to Boost the Bioeconomy

A new Executive Order in the U.S. aims to ease the path to market for products that use synthetic biology or genome editing. Emily Marden explains the thinking behind the announcement and its efforts to streamline the current U.S. framework for biotech.

Resources

 

Upcoming Events

SUBSCRIBE

To receive email alerts when we post a blog entry, please provide your name and email address.

Archives

Categories